Skip to Main Content

Hello, everyone, and how are you this morning? A spot of rain is falling on the Pharmalot campus, making for a gloomy start to yet another busy day. Nothing like a soggy start, is there? Nonetheless, we will muddle onward, fortified by a cup or more of needed stimulation. Please feel free to join us. Our choice today is the ever-tasty bourbon pecan. Meanwhile, we are passing along some tidbits that we hope you will find useful. Have a good day, stay dry, and keep us in mind if you hear anything interesting. …

Biogen and other drugmakers have already hinted they might sue Medicare over its decision to limit coverage for the controversial new drug, Aduhelm — a legal challenge that could have massive implications for patients and pharmaceutical companies that extend far beyond those focused on Alzheimer’s disease, STAT explains. Even before the Centers for Medicare & Medicaid Services made limits on the drug official last week, Biogen had said it did not believe such restrictions would hold up in court. Other drugmakers potentially impacted by the decision, such as Eli Lilly, raised similar objections. And a number of experts acknowledge that drugmakers have a shot at challenging the decision.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment